Your browser doesn't support javascript.
loading
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini, Ilaria; Revandkar, Ajinkya; D'Ambrosio, Mariantonietta; Colucci, Manuel; Pasquini, Emiliano; Mosole, Simone; Troiani, Martina; Brina, Daniela; Sheibani-Tezerji, Raheleh; Elia, Angela Rita; Rinaldi, Andrea; Pernigoni, Nicolò; Rüschoff, Jan Hendrik; Dettwiler, Susanne; De Marzo, Angelo M; Antonarakis, Emmanuel S; Borrelli, Costanza; Moor, Andreas E; Garcia-Escudero, Ramon; Alajati, Abdullah; Attanasio, Giuseppe; Losa, Marco; Moch, Holger; Wild, Peter; Egger, Gerda; Alimonti, Andrea.
Afiliação
  • Guccini I; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Institute of Molecular Health Sciences, ETH Zurich, Zurich 8093, Switzerland.
  • Revandkar A; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • D'Ambrosio M; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne 1011, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Colucci M; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne 1011, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Pasquini E; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Mosole S; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Troiani M; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Brina D; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Sheibani-Tezerji R; Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.
  • Elia AR; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Rinaldi A; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Pernigoni N; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Rüschoff JH; Department of Pathology and Molecular Pathology, University Hospital Zurich (USZ), Zurich 8091, Switzerland.
  • Dettwiler S; Department of Pathology and Molecular Pathology, University Hospital Zurich (USZ), Zurich 8091, Switzerland.
  • De Marzo AM; Departments of Pathology, Urology and Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
  • Antonarakis ES; Departments of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Borrelli C; Department of Biosystems Science and Engineering, ETH Zurich, Basel 4058, Switzerland.
  • Moor AE; Department of Biosystems Science and Engineering, ETH Zurich, Basel 4058, Switzerland.
  • Garcia-Escudero R; Molecular Oncology Unit, CIEMAT, Madrid 28040, Spain; Biomedicine Research Institute, Hospital 12 Octubre, Madrid 28041, Spain; CIBERONC, Madrid 28029, Spain.
  • Alajati A; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Attanasio G; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland.
  • Losa M; Anatomical Pathology Specialization Unit, Toma Advanced Biomedical Assay, Busto Arsizio 21052, Italy.
  • Moch H; Department of Pathology and Molecular Pathology, University Hospital Zurich (USZ), Zurich 8091, Switzerland.
  • Wild P; Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, 60596 Frankfurt Am Main, Germany; Frankfurt Institute for Advanced Studies (FIAS), Frankfurt 60438, Germany.
  • Egger G; Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria; Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.
  • Alimonti A; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano 6900, Switzerland; Department of Medicine, University of Padua, Padua 35128, Italy; Department of Health Sciences and Technology (D-HEST)
Cancer Cell ; 39(1): 68-82.e9, 2021 01 11.
Article em En | MEDLINE | ID: mdl-33186519
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Deleção de Genes / Inibidor Tecidual de Metaloproteinase-1 / PTEN Fosfo-Hidrolase / Docetaxel Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Deleção de Genes / Inibidor Tecidual de Metaloproteinase-1 / PTEN Fosfo-Hidrolase / Docetaxel Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça País de publicação: Estados Unidos